Akoya Reports 53% Revenue Growth in the Second Quarter of 2021
MARLBOROUGH, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced…
Pharmaceuticals, Biotechnology and Life Sciences
MARLBOROUGH, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced…
U.S. FDA reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); On…
– Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected by the End of 2021…
Enrollment on track in both Phase 2b chronic pain studies with NYX-2925—data readouts expected 1H 2022 Enrollment on track in…
– Phase 3 trial to evaluate apitegromab in patients with non-ambulatory Type 2 and Type 3 spinal muscular atrophy (SMA)…
– Conference call and webcast today at 4:30 p.m. ET – SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading…
Clearance of IND for Treatment of Polycystic Ovary Syndrome New Patent Broadens Tildacerfont Intellectual Property Estate in Congenital Adrenal Hyperplasia…
Second Quarter 2021 Revenue of $11.9 Million Increased 180% and Lung Diagnostic Revenue of $4.8 Million Increased 109% over Second…
Announced positive topline results from the EQUATE study of itolizumab in first-line treatment of acute graft-versus-host disease Announced plans to…
Fourth Consecutive Quarter of Record Results Highlights for Second Quarter 2021: Record revenues of $18.1 million, a 125% increase compared…